Gene-surrogate | Flexible two-phase design options | Expected Phase One counts | Power# | Cost* | |||||
---|---|---|---|---|---|---|---|---|---|
Spec | Sens | n0 | n1 | ρ0† | ρ1‡ | N0 | N1 | ||
70% | 80% | 800 | 400 | 90% | 90% | 5902 | 1373 | 83% | 1564 |
70% | 90% | 800 | 400 | 90% | 90% | 5882 | 1325 | 87% | 1560 |
80% | 60% | 800 | 400 | 90% | 90% | 8824 | 1988 | 87% | 1741 |
80% | 70% | 800 | 400 | 90% | 90% | 8780 | 1889 | 91% | 1733 |
80% | 80% | 800 | 400 | 90% | 90% | 8738 | 1800 | 94% | 1727 |
80% | 90% | 800 | 400 | 90% | 90% | 8696 | 1718 | 96% | 1720 |
90% | 60% | 900 | 300 | 90% | 90% | 19286 | 2000 | 98% | 2264 |
90% | 70% | 900 | 300 | 90% | 90% | 19104 | 2000 | 99% | 2255 |
90% | 80% | 900 | 300 | 90% | 90% | 18925 | 1960 | 99.6% | 2244 |
90% | 90% | 900 | 300 | 90% | 90% | 18750 | 1835 | 99.8% | 2229 |